Wilbur Pan — Merck & Co., Inc., Rahway, NJ, USA (United States)

Area of research

Oncology · Cancer Research

Research interest

Research interests include Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, and Cancer Treatment and Pharmacology.

Recent publications

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Annals of Oncology 2024cited by 141position: middledoi

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

JNCI Journal of the National Cancer Institute 2024cited by 31position: middledoi

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

npj Breast Cancer 2024cited by 19position: middledoi

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

New England Journal of Medicine 2022cited by 1,053position: middledoi

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.

Journal of Clinical Oncology 2022cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Looking for a research collaborator?

Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.

Find collaborators in Oncology · Cancer Research →